Drug Doubles Survival Promise
9:50–10:29 · 39s
Washington Post reporter Carolyn Johnson explains how a KRAS-targeting pill has electrified the field by roughly doubling median survival in a pancreatic cancer trial and is now on an FDA fast track.
9:50–10:29 · 39s
Washington Post reporter Carolyn Johnson explains how a KRAS-targeting pill has electrified the field by roughly doubling median survival in a pancreatic cancer trial and is now on an FDA fast track.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.